Real-world analysis of patients with CLL treated with ibrutinib: a retrospective analysis of Brazilian Registry of CLL

Abstract: Although ibrutinib improves survival and prolongs responses with less toxicity than chemoimmunotherapy, some patients still discontinue treatment due to intolerance and toxicity. This study is a large real-world analysis of Latin American patients and included 310 patients from 32 centers....

Cijeli opis

Bibliografski detalji

Glavni autori:	Verena Pfister, Fernanda de Morais Marques, Talita Silveira, Jayr Schmidt Filho, Vinicius Campos de Molla, Matheus Vescovi Gonçalves, Mihoko Yamamoto, Rodrigo Santucci, Milton Aranha, Danielle Leão Cordeiro de Farias, Phillip Scheinberg, Henrique Nunes Pêcego, Glaciano Ribeiro, Vera P. Figueiredo, Leila Perobelli, Valeria Buccheri, Adriana Scheliga, Nelson Hamerschlak, Abel Costa, Carlos Sérgio Chiattone, Celso Arrais-Rodrigues
Format:	Artigo
Jezik:	Inglês
Izdano:	Elsevier 2025-12-01
Serija:	Blood Global Hematology
Online pristup:	http://www.sciencedirect.com/science/article/pii/S3050565825000198
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!